作为我们不断努力寻找新型抑制癌症相关CA IX和XII亚型的候选抗癌药物的一部分，我们在这里描述了设计和合成2-芳基-喹唑啉-4-基氨基苯甲酸衍生物（6a-c，7a-c和8a-c）作为新型的非经典CA抑制剂。 鉴于其在抗癌药物发现和开发有效的CAIs方面的重要性，4-苯胺喹唑啉特权骨架在该研究中得到了利用。 然后，在苯胺基团的正交（6a-c），间位（7a-c）或邻位（8a-c）添加了自由羧酸官能团，以提供目标抑制剂。 所有化合物都被评估其对hCA I，II（胞质），IX和XII（跨膜，肿瘤相关）亚型的抑制活性。 此外，六种喹唑啉物质（6a-c，7b和8a-b）被NCI-USA选中，进行了对代表九个肿瘤子板块的59种人类癌细胞系的体外抗增殖活性评估。

As part of our ongoing endeavour to identify novel inhibitors of cancer-associated CA isoforms IX and XII as possible anticancer candidates, here we describe the design and synthesis of small library of 2-aryl-quinazolin-4-yl aminobenzoic acid derivatives (6a-c, 7a-c, and 8a-c) as new non-classical CA inhibitors. On account of its significance in the anticancer drug discovery and in the development of effective CAIs, the 4-anilinoquinazoline privileged scaffold was exploited in this study. Thereafter, the free carboxylic acid functionality was appended in the ortho (6a-c), meta (7a-c), or para-positon (8a-c) of the anilino motif to furnish the target inhibitors. All compounds were assessed for their inhibitory activities against the hCA I, II (cytosolic), IX, and XII (trans-membrane, tumour-associated) isoforms. Moreover, six quinazolines (6a-c, 7b, and 8a-b) were chosen by the NCI-USA for in vitro anti-proliferative activity evaluation against 59 human cancer cell lines representing nine tumour subpanels.